Gilead Deepens R&D Investment with US$10 B Galapagos Deal
By Michelle Liu
Pharma Deals Review: Vol 2019 Issue 7 (Table of Contents)
Published: 19 Jul-2019
DOI: 10.3833/pdr.v2019.i7.2440 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In its largest deal of 2019 so far, Gilead Sciences has signed a 10-year collaboration with Galapagos to gain the license and option rights to all current and future Galapagos programmes in all countries outside Europe for a total deal value of up to US$9...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS